Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer

Published:2014-01 Issue:1 Volume:9 Page:121-125
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Chiappori Alberto,Williams Charles,Northfelt Donald W.,Adams John W.,Malik Shakun,Edelman Martin J.,Rosen Peter,Van Echo David A.,Berger Mark S.,Haura Eric B.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

2. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group;Fossella;J Clin Oncol,2000

3. The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes;Berrieman;Cancer,2005

4. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis;Nguyen;Proc Natl Acad Sci USA,2007

5. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer;Chiappori;Br J Cancer,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dissection of the cell communication interactions in lung adenocarcinoma identified a prognostic model with immunotherapy efficacy assessment and a potential therapeutic candidate gene ITGB1;Heliyon;2024-09

2. Relationships of Prodiginins Mechanisms and Molecular Structures to their Antiproliferative Effects;Anti-Cancer Agents in Medicinal Chemistry;2024-08-07

3. Precise Molecular Subtyping Reveals Heterogeneity of Lung Adenocarcinoma Based on DNA Methylation;Current Medicinal Chemistry;2024-06-05

4. Crosstalk between metabolism and cell death in tumorigenesis;Molecular Cancer;2024-04-04

5. Bcl-2 pathway inhibition in solid tumors: a review of clinical trials;Clinical and Translational Oncology;2023-01-13